Key Developments: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

26.36USD
4:00pm EDT
Price Change (% chg)

$-0.92 (-3.37%)
Prev Close
$27.28
Open
$27.09
Day's High
$27.19
Day's Low
$26.13
Volume
68,644
Avg. Vol
101,398
52-wk High
$30.99
52-wk Low
$12.96

Search Stocks

Latest Key Developments (Source: Significant Developments)

Chimerix and BARDA announce continued partnership in the development of Brincidofovir for Smallpox
Tuesday, 2 Sep 2014 08:01am EDT 

Chimerix Inc:Says award of $17.0 mln through the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of its broad spectrum antiviral brincidofovir as a medical countermeasure to treat smallpox.Receives the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox.Contract extension provides an additional $17.0 million to Chimerix for a period of 15 months, and will support Phase 3 trials expected to initiate in the second half of 2014.  Full Article

Chimerix Inc announces completion of public offering of common stock
Tuesday, 27 May 2014 04:01pm EDT 

Chimerix Inc:Completion of underwritten public offering of 8,395,000 shares of its common stock, including 1,095,000 shares sold pursuant to full exercise of option previously granted to the underwriters to purchase additional shares of common stock.All of shares were offered by Chimerix at a price to the public of $14.22 per share.Gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were about $119.4 mln.Chimerix anticipates using net proceeds to fund its research and development efforts and for general corporate purposes, including working capital.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as joint book-running managers for offering.Cowen and Company, LLC acted as co-lead manager for the offering, and William Blair & Company, L.L.C. and Canaccord Genuity Inc. acted as co-managers for the offering.  Full Article

Chimerix Inc announces commencement of public offering of common stock
Monday, 19 May 2014 04:01pm EDT 

Chimerix Inc:Says it is offering to sell 6,200,000 shares of its common stock in an underwritten public offering.In connection with this offering, Chimerix will also grant to underwriters a 30-day option to purchase up to an aggregate of 930,000 additional shares of common stock.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering and Cowen and Company, LLC is acting as co-lead manager for the offering.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.  Full Article

Chimerix Inc appoints new chief executive officer and president
Wednesday, 9 Apr 2014 09:00am EDT 

Chimerix Inc:Appoints M. Michelle Berrey to the position of president and chief executive officer.Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests.In addition Berrey will continue to serve as Chimerix's Chief Medical Officer.  Full Article

Chimerix Inc to provide brincidofovir to Josh Hardy as first patient in new open-label study in patients with adenovirus infections
Tuesday, 11 Mar 2014 07:57pm EDT 

Chimerix Inc:Reaches agreement with U.S. Food and Drug Administration (FDA) for immediate initiation of pilot trial of open-label brincidofovir for treatment of adenovirus infections in immunocompromised patients.FDA has committed to work expeditiously with Chimerix on design of pivotal Phase 3 study that would be continuation of this pilot study.Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between FDA and Chimerix regarding need for additional clinical development to assess brincidofovir's potential in adenovirus infection.This study is expected to begin with Josh Hardy as the first patient enrolled on March 12.  Full Article

Chimerix Inc Announces Completion Of Secondary Offering Of Common Stock
Wednesday, 23 Oct 2013 04:54pm EDT 

Chimerix, Inc announced that the completion of an underwritten public offering of 2,476,995 shares of its common stock at a price to the public of $16.50 per share. All of the shares were sold by certain existing stockholders. Chimerix did not receive any proceeds from the sale of the shares. The principal purposes of the offering are to facilitate an orderly distribution of shares and to increase the Company's public float. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 371,549 shares of common stock to cover over-allotments. Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. and Canaccord Genuity Inc. are acting as co-managers for the offering.  Full Article

Chimerix Inc Announces Pricing Of Secondary Offering of Common Stock
Friday, 18 Oct 2013 09:40am EDT 

Chimerix, Inc announced that the pricing of an underwritten public offering of 2,476,995 shares of its common stock at a price to the public of $16.50 per share. All of the shares are being sold by certain existing stockholders. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 371,549 shares of common stock to cover over-allotments, if any. The offering is expected to close on October 23, 2013, subject to customary closing conditions. Chimerix will not receive any proceeds from the sale of the shares. The principal purposes of the offering are to facilitate an orderly distribution of shares and to increase the company's public float. Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. and Canaccord Genuity Inc. are acting as co-managers for the offering.  Full Article

Chimerix Inc Announces Proposed Public Offering of Common Stock
Tuesday, 8 Oct 2013 08:00am EDT 

Chimerix, Inc announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for certain stockholders of Chimerix to offer shares of common stock in an underwritten public offering. Chimerix will not receive any proceeds from the sale of the shares. The principal purposes of the offering are to facilitate an orderly distribution of shares and to increase the Company's public float. Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Chimerix Inc Announces Publication Of Positive Phase 2 Results Of Brincidofovir (CMX001) In New England Journal Of Medicine
Thursday, 26 Sep 2013 08:02am EDT 

Chimerix, Inc announced the publication of results from its Phase 2 Study CMX001-201 evaluating brincidofovir (CMX001) for the prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) recipients. The article, entitled "CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation," appears in the September 26th issue of the New England Journal of Medicine (N Engl J Med 369:1227-36).  Full Article

Chimerix Inc Announces Completion of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
Tuesday, 16 Apr 2013 10:11am EDT 

Chimerix Inc announced the completion of its initial public offering of 8,418,000 shares of its common stock at an initial public offering price of $14.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,098,000 additional shares of common stock. Chimerix's common stock is listed on the NASDAQ Global Market under the trading symbol CMRX. Chimerix expects to use the net proceeds from the offering primarily for research and development expenses related to CMX001, as well as for general corporate purposes. Morgan Stanley and Cowen and Company acted as joint book-running managers for the offering. William Blair and Lazard Capital Markets acted as co-managers.  Full Article

Chimerix says antiviral shows promise against Ebola

- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

Search Stocks